NDAORALTABLET, DELAYED RELEASE
Approved
Apr 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
VIMOVO (esomeprazole magnesium; naproxen) by Amgen is immediate-release esomeprazole magnesium layer and an enteric-coated naproxen core. Approved for adolescent patients 12 years of age, older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and 3 more indications. First approved in 2010.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIMOVO is a fixed-dose combination of esomeprazole magnesium (proton pump inhibitor) and naproxen (NSAID) delivered via a dual-layer tablet designed to release esomeprazole first in the stomach, then enteric-coated naproxen in the small intestine. It is indicated for symptomatic relief of arthritis in adolescents and adults while reducing the risk of naproxen-associated gastric ulcers. The mechanism combines prostaglandin synthetase inhibition (naproxen) with gastric acid suppression via H/K-ATPase inhibition (esomeprazole).
$0.003BPart D
LOE ApproachingAs a product approaching loss of exclusivity with modest Part D spending (~$3M annually), VIMOVO brand teams face contracting resources and shifting focus toward transition planning and generic partnership strategies.
Mechanism of Action
immediate-release esomeprazole magnesium layer and an enteric-coated naproxen core. As a result, esomeprazole is released first in the stomach, prior to the dissolution of naproxen in the small intestine. The enteric coating prevents naproxen release at pH levels below 5.5. Naproxen is a NSAID with…
Indications (6)
Worked on VIMOVO at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.